AI Analysis
AI-generated analysis. Always verify with the original filing.
Net loss expanded 57.0% to -$8.9M from -$5.7M as the Company advanced its biopharma transformation, while operating cash burn increased to -$7.0M amid working capital shifts and the launch of Velocity Bioworks CDMO.
Key Takeaways
1Net loss widened 57.0% to -$8.9M from -$5.7M, reflecting investments in product innovation and development during the strategic pivot to biopharma.
2Operating cash outflow rose to -$7.0M from -$5.7M, driven by changes in net operating assets and liabilities including increases in accounts payable.
3Free cash flow was -$7.0M after $38K in capital expenditures, down from prior-year operating outflow levels as capex declined from $118K.
4Launched Velocity Bioworks, Inc. CDMO subsidiary in December 2025 to gain manufacturing control, introducing new operational dynamics while maintaining a small core team.
5Reduced headcount intentionally to lower operating expenses, supporting cost discipline amid the transition to focused biopharma operations.